Summary
Methamphetamine (METH) is recognized as one of the most abused psychostimulants in the USA. METH is an illicit drug that is known to exert neurotoxic effects on both dopaminergic and serotonergic neural systems. Our laboratory has been studying the biochemical mechanisms underlying MDMA and METH-induced neurotoxic effects both in vivo and in vitro. Our substance abuse research focuses on the global alteration of cortical protein expression in rats treated with acute METH. Altered protein expression was identified using a multistep protein separation/proteomic platform. Differential changes of the selected proteins were further confirmed by quantitative immunoblotting. Our study identified 82 differentially expressed proteins, 40 of which were downregulated and 42 of which were upregulated post acute METH treatment. Proteins that were shown to be downregulated included collapsin response mediator protein-2 (CRMP-2), superoxide dismutase 1 (SOD 1), and phosphatidylethanolamine-binding protein-1 (PEBP-1). Proteins that were shown to be upregulated included authophagy-linked microtubule-associated protein light chain 3 (LC3), synapsin-1, and Parkinsonism-linked ubiquitin carboxy-terminal hydroxylase-L1 (UCH-L1). This differential protein expression highlights on the neurotoxic mechanism involved in METH exposure as well as to discover potential markers for METH-induced neurotoxicity. In this chapter, we describe the current protocols for the in vivo rat model of acute METH treatment (40 mg/kg) coupled with the description of the multistep separation platform applied. These methods and protocols are discussed in the paradigm of acute model of methamphetamine drug abuse and can be applied to other models of substance abuse such as to MDMA or cocaine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Perez, J. A., Jr., Arsura, E. L., and Strategos, S. (1999) Methamphetamine-related stroke: four cases, J. Emerg. Med. 17, 469–471.
Lan, K. C., Lin, Y. F., Yu, F. C., Lin, C. S., and Chu, P. (1998) Clinical manifestations and prognostic features of acute methamphetamine intoxication, J. Formos. Med. Assoc. 97, 528–533.
NSDUH Report (2006) Methamphetamine use, abuse, and dependence: 2002–2004, National Survey on Drug Use and Health, http://www.oas.samhsa.gov/2k7/meth/meth.cfm (accessed on November 11, 2008).
Sokolov, B. P., and Cadet, J. L. (2006) Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness, Neuropsychopharmacology 31, 956–966.
Warren, M. W., Zheng, W., Kobeissy, F. H., Cheng Liu, M., Hayes, R. L., Gold, M. S., Larner, S. F., and Wang, K. K. (2006) Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure, Int. J. Neuropsychopharmacol. 9, 1–11.
Jimenez, A., Jorda, E. G., Verdaguer, E., Pubill, D., Sureda, F. X., Canudas, A. M., Escubedo, E., Camarasa, J., Camins, A., and Pallas, M. (2004) Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells, Toxicol. Appl. Pharmacol. 196, 223–234.
Pu, C., Broening, H. W., and Vorhees, C. V. (1996) Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex, Synapse 23, 328–334.
Bowyer, J. F., Pogge, A. R., Delongchamp, R. R., O’Callaghan, J. P., Patel, K. M., Vrana, K. E., and Freeman, W. M. (2007) A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes, Neuroscience 144, 66–76.
Cadet, J. L., Ordonez, S. V., and Ordonez, J. V. (1997) Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2, Synapse 25, 176–184.
Cadet, J. L., Jayanthi, S., and Deng, X. (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis, FASEB J. 17, 1775–1788.
Jayanthi, S., Deng, X., Noailles, P. A., Ladenheim, B., and Cadet, J. L. (2004) Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades, FASEB J. 18, 238–251.
Staszewski, R. D., and Yamamoto, B. K. (2006) Methamphetamine-induced spectrin proteolysis in the rat striatum, J. Neurochem. 96, 1267–1276.
Warren, M. W., Kobeissy, F. H., Liu, M. C., Hayes, R. L., Gold, M. S., and Wang, K. K. (2006) Ecstasy toxicity: a comparison to methamphetamine and traumatic brain injury, J. Addict. Dis. 25, 115–123.
Warren, M. W., Kobeissy, F. H., Liu, M. C., Hayes, R. L., Gold, M. S., and Wang, K. K. (2005) Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury, Life Sci. 78, 301–309.
Wallace, T. L., Vorhees, C. V., Zemlan, F. P., and Gudelsky, G. A. (2003) Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain, Neuroscience 116, 1063–1068.
Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., and Sulzer, D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis, J. Neurosci. 22, 8951–8960.
Kanthasamy, A., Anantharam, V., Ali, S. F., and Kanthasamy, A. G. (2006) Methamphetamine induces autophagy and apoptosis in a mesencephalic dopaminergic neuronal culture model: role of cathepsin-D in methamphetamine-induced apoptotic cell death, Ann. NY Acad. Sci. 1074, 234–244.
Kobeissy, F. H., Warren, M. W., Ottens, A. K., Sadasivan, S., Zhang, Z., Gold, M. S., and Wang, K. K. (2008) Psychoproteomic analysis of rat cortex following acute methamphetamine exposure, J. Proteome Res. 7, 1971–1983.
Ottens, A. K., Kobeissy, F. H., Wolper, R. A., Haskins, W. E., Hayes, R. L., Denslow, N. D., and Wang, K. K. (2005) A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry, Anal. Chem. 77, 4836–4845.
Kobeissy, F. H., Sadasivan, S., Zheng, Z., Gold, M. S., and Wang, K. K. W. (2008) Psychiatric    research:    psychoproteomics, degradomics and systems biology. Expert Rev. Proteomics 5, 293–314.
Acknowledgments
The author would like to thank Dr. Matthew Warren for the technical assistance. This work was supported in part by the Donald and Irene Dizney Eminent Scholar Chair, held by Mark S. Gold, M.D., Distinguished Professor, McKnight Brain Institute and also by the Department of Defense (DOD) grant #DAMD17-03-1-0066, NIH grant #R01 NS049175-01 A1.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kobeissy, F.H., Zhang, Z., Sadasivan, S., Gold, M.S., Wang, K.K.W. (2009). Methods in Drug Abuse Neuroproteomics: Methamphetamine Psychoproteome. In: Ottens, A., Wang, K. (eds) Neuroproteomics. Methods in Molecular Biology, vol 566. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59745-562-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-59745-562-6_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-934115-84-8
Online ISBN: 978-1-59745-562-6
eBook Packages: Springer Protocols